Project Grant R01CA303155
Award Date 7/9/26
Completion Date 6/30/31
Dollars Obligated $530K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $463,279 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. The award supports research investigating USP1 (ubiquitin-specific peptidase 1) inhibition as a therapeutic strategy to overcome PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOC). The research deliverables include...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $707,798 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, and concluding March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-resistant form within months of standard-of-care treatment. The primary deliverable is...
- Federal Grant Award Summary Brigham and Women's Hospital, Inc. received a $772,208 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 10, 2026, through March 31, 2031. The grant funds research on macrophage-directed strategies to enhance PARP (poly(ADP-ribose) polymerase) inhibitor efficacy in BRCA-associated breast cancer. The project delivers two primary research products: (1) translational biomarker analysis...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a Project Grant of $770,666 to the University of Colorado's Office of Contracts and Grants (awarded March 19, 2026; completion February 28, 2028) to conduct fundamental research on splicing-mediated dysregulation of interferon signaling in cancer. The project investigates how transposon-derived exonization creates altered protein isoforms of the IFNAR2 gene that...
- Federal Grant Award Summary Dana-Farcer Cancer Institute, Inc. received a $718,275 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. The award supports fundamental research investigating context-specific pathway dependencies for nuclear envelope (NE) proteins in brain cancer. The project employs large-scale human cancer cell fitness screens and an analytical framework called WEBSTER to...
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received a $740,020 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective May 11, 2026, with a completion date of April 30, 2031. The grant supports translational research aimed at optimizing neoadjuvant and adjuvant anti-programmed cell death-1 (anti-PD-1) immunotherapy for patients with localized renal cell carcinoma (RCC) at high risk of...
- Federal Grant Award Summary The National Cancer Institute awarded Boston Children's Hospital a $578,559 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on the tumor suppressor function of P190 RhoGAP. The research program investigates how the ARHGAP35 gene product P190A regulates cell proliferation and survival through the Hippo signaling pathway, with particular focus on understanding how...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...